Centro Universitário FMABC, Clinical Analysis Laboratory - Santo André (SP), Brazil.
Centro Universitário São Camilo - São Paulo (SP), Brazil.
Rev Assoc Med Bras (1992). 2023 Oct 30;69(12):e20230812. doi: 10.1590/1806-9282.20230812. eCollection 2023.
The aim of this study was to investigate the role of irisin in type 2 diabetes mellitus and its association with metabolic alterations and obesity.
A cross-sectional case-control study was conducted on participants treated at Centro Universitário FMABC between August 2018 and July 2019, by comparing a control group (n=14) with type 2 diabetes mellitus patients (n=16). The control group consisted of participants aged above 21 years with no chronic diseases, diabetes, smoking, or illicit drug use. The type 2 diabetes mellitus group included patients aged above 21 years, who were diagnosed with type 2 diabetes for at least 5 years (glycated hemoglobin>7%). Exclusion criteria were not willing to continue, recent hospitalization, and failure to meet inclusion criteria. Biochemical parameters included blood glucose, glycated hemoglobin, plasma irisin levels, and irisin gene expression in peripheral blood.
Type 2 diabetes mellitus patients exhibited significantly higher plasma glucose levels [143 (40) vs. 92 (13) mg/dL, *p<0.05] and glycated hemoglobin levels [7.1% (1.6) vs. 5.6% (0.5), *p<0.05] compared to the control group. Irisin gene expression in type 2 diabetes mellitus patients was lower 0.02288 (0.08050) than the control group 8.506e-006 (1.412e-005) (p=0.06). Correlation analysis revealed a positive association between irisin expression and body mass index in type 2 diabetes mellitus (Rho=0.5221, 95%CI -0.058 to 0.838, p=0.06), while plasma irisin showed a negative correlation with body mass index (Rho=-0.656, 95%CI -0.836 to 0.215, p=0.03). No significant correlations were found between plasma glucose or glycated hemoglobin levels and irisin expression.
The data suggests that body mass index directly influences plasma irisin levels and the regulation of irisin gene expression, possibly linking irisin to adiposity changes observed in obesity-related type 2 diabetes mellitus.
本研究旨在探讨鸢尾素在 2 型糖尿病中的作用及其与代谢改变和肥胖的关系。
本研究采用病例对照研究，比较了 2018 年 8 月至 2019 年 7 月在 Centro Universitário FMABC 治疗的对照组（n=14）和 2 型糖尿病组（n=16）。对照组由年龄在 21 岁以上、无慢性病、糖尿病、吸烟或使用非法药物的参与者组成。2 型糖尿病组包括年龄在 21 岁以上、至少患有 5 年（糖化血红蛋白>7%）2 型糖尿病的患者。排除标准为不愿继续、近期住院和不符合纳入标准。生化参数包括血糖、糖化血红蛋白、血浆鸢尾素水平和外周血鸢尾素基因表达。
与对照组相比，2 型糖尿病组的血浆葡萄糖水平[143（40）vs. 92（13）mg/dL，*p<0.05]和糖化血红蛋白水平[7.1%（1.6）vs. 5.6%（0.5），*p<0.05]明显更高。2 型糖尿病组鸢尾素基因表达为 0.02288（0.08050），低于对照组 8.506e-006（1.412e-005）（p=0.06）。相关性分析显示，2 型糖尿病患者的鸢尾素表达与体重指数呈正相关（Rho=0.5221，95%CI -0.058 至 0.838，p=0.06），而血浆鸢尾素与体重指数呈负相关（Rho=-0.656，95%CI -0.836 至 0.215，p=0.03）。血浆葡萄糖或糖化血红蛋白水平与鸢尾素表达之间无显著相关性。
数据表明，体重指数直接影响血浆鸢尾素水平和鸢尾素基因表达的调节，可能将鸢尾素与肥胖相关 2 型糖尿病中观察到的肥胖变化联系起来。
